Annovis Bio, Inc. Financing Cash Flow
Annovis Bio, Inc. (ANVS) reported Financing Cash Flow of $30.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Annovis Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $26.42M.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $3.70M, a 81.31% decline year-over-year.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $13.17M, a 112.45% increase year-over-year.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.64M, a 86.12% decline year-over-year.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $34.60M, a 29.63% increase from fiscal 2024.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $26.69M, a 53.89% increase from fiscal 2023.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $17.34M, a 375888.10% increase from fiscal 2022.
- Annovis Bio, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $4.61K, a 99.99% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $30.12M 10-Q · filed 2026-08-14 | $43.29M derived: sum of 3 quarters · filed 2026-08-14 | $44.94M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.70M 10-Q · filed 2026-05-15 | $16.87M derived: sum of 2 quarters · filed 2026-05-15 | $18.52M derived: sum of 3 quarters · filed 2026-05-15 | $18.52M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $13.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $14.82M derived: sum of 2 quarters · filed 2026-03-13 | $14.82M derived: sum of 3 quarters · filed 2026-08-14 | $34.60M 10-K · filed 2026-03-13 |
| 2025-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.64M derived: sum of 2 quarters · filed 2026-08-14 | $21.43M 10-Q · filed 2025-11-12 | $27.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $19.78M 10-Q · filed 2026-08-14 | $25.98M derived: sum of 3 quarters · filed 2026-08-14 | $37.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $19.78M 10-Q · filed 2026-05-15 | $25.98M derived: sum of 2 quarters · filed 2026-05-15 | $37.82M derived: sum of 3 quarters · filed 2026-05-15 | $42.06M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $18.04M derived: sum of 2 quarters · filed 2026-03-13 | $22.28M derived: sum of 3 quarters · filed 2026-03-13 | $26.69M 10-K · filed 2026-03-13 |
| 2024-09-30 | $11.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.08M derived: sum of 2 quarters · filed 2025-11-12 | $20.49M 10-Q · filed 2025-11-12 | $29.26M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $8.65M 10-Q · filed 2025-08-12 | $17.42M derived: sum of 3 quarters · filed 2025-08-12 | $17.42M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $4.42M 10-Q · filed 2025-05-13 | $13.18M derived: sum of 2 quarters · filed 2025-05-13 | $13.18M derived: sum of 3 quarters · filed 2025-05-13 | $21.75M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $8.76M derived: sum of 2 quarters · filed 2025-03-21 | $17.34M derived: sum of 3 quarters · filed 2025-03-21 | $17.34M 10-K · filed 2025-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $8.57M derived: sum of 2 quarters · filed 2024-11-08 | $8.58M 10-Q · filed 2024-11-08 | $8.58M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $8.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.58M 10-Q · filed 2024-08-14 | $8.58M derived: sum of 3 quarters · filed 2024-08-14 | $8.58M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $7.39K 10-Q · filed 2024-05-10 | $7.39K derived: sum of 2 quarters · filed 2024-05-10 | $7.39K derived: sum of 3 quarters · filed 2024-05-10 | $7.39K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $4.61K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $4.61K 10-Q · filed 2023-11-08 | $4.61K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $4.61K 10-Q · filed 2023-08-14 | $4.61K derived: sum of 3 quarters · filed 2023-08-14 | -$20.84K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $4.61K 10-Q · filed 2023-05-10 | $4.61K derived: sum of 2 quarters · filed 2023-05-10 | -$20.84K derived: sum of 3 quarters · filed 2023-05-10 | $46.75M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$25.46K derived: sum of 2 quarters · filed 2023-03-31 | $46.74M derived: sum of 3 quarters · filed 2023-03-31 | $46.74M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$25.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $46.74M derived: sum of 2 quarters · filed 2022-11-08 | $46.74M 10-Q · filed 2022-11-08 | $46.74M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $46.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $46.77M 10-Q · filed 2022-08-08 | $46.77M derived: sum of 3 quarters · filed 2022-08-08 | $46.77M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $3.02K 10-Q · filed 2022-05-04 | $3.02K derived: sum of 2 quarters · filed 2022-05-04 | $3.02K derived: sum of 3 quarters · filed 2022-05-04 | -$42.37K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | -$45.39K derived: sum of 3 quarters · filed 2022-03-02 | $12.04M 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$45.39K derived: sum of 2 quarters · filed 2021-11-03 | $12.04M 10-Q · filed 2021-11-03 | $12.04M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | -$45.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $12.04M 10-Q · filed 2021-07-28 | $12.04M derived: sum of 3 quarters · filed 2021-07-28 | $12.04M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $12.09M 10-Q · filed 2021-05-06 | $12.09M derived: sum of 2 quarters · filed 2021-05-06 | $12.08M derived: sum of 3 quarters · filed 2021-05-06 | $12.00M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$1.86K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$5.48K derived: sum of 2 quarters · filed 2021-03-03 | -$86.91K derived: sum of 3 quarters · filed 2021-03-03 | $443.09K 10-K · filed 2021-03-03 |
| 2019-09-30 | -$3.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$85.05K derived: sum of 2 quarters · filed 2020-11-04 | $444.95K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$81.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $448.57K 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | $530.00K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |